These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 20359476)

  • 1. Genetic evidence that SOST inhibits WNT signaling in the limb.
    Collette NM; Genetos DC; Murugesh D; Harland RM; Loots GG
    Dev Biol; 2010 Jun; 342(2):169-79. PubMed ID: 20359476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity.
    Ellies DL; Viviano B; McCarthy J; Rey JP; Itasaki N; Saunders S; Krumlauf R
    J Bone Miner Res; 2006 Nov; 21(11):1738-49. PubMed ID: 17002572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sost and its paralog Sostdc1 coordinate digit number in a Gli3-dependent manner.
    Collette NM; Yee CS; Murugesh D; Sebastian A; Taher L; Gale NW; Economides AN; Harland RM; Loots GG
    Dev Biol; 2013 Nov; 383(1):90-105. PubMed ID: 23994639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor.
    Semënov M; Tamai K; He X
    J Biol Chem; 2005 Jul; 280(29):26770-5. PubMed ID: 15908424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sost downregulation and local Wnt signaling are required for the osteogenic response to mechanical loading.
    Tu X; Rhee Y; Condon KW; Bivi N; Allen MR; Dwyer D; Stolina M; Turner CH; Robling AG; Plotkin LI; Bellido T
    Bone; 2012 Jan; 50(1):209-17. PubMed ID: 22075208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Wnt inhibitors Dkk1 and Sost are downstream targets of BMP signaling through the type IA receptor (BMPRIA) in osteoblasts.
    Kamiya N; Kobayashi T; Mochida Y; Yu PB; Yamauchi M; Kronenberg HM; Mishina Y
    J Bone Miner Res; 2010 Feb; 25(2):200-10. PubMed ID: 19874086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LRP5 mutations linked to high bone mass diseases cause reduced LRP5 binding and inhibition by SOST.
    Semenov MV; He X
    J Biol Chem; 2006 Dec; 281(50):38276-84. PubMed ID: 17052975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversing LRP5-dependent osteoporosis and SOST deficiency-induced sclerosing bone disorders by altering WNT signaling activity.
    Chang MK; Kramer I; Keller H; Gooi JH; Collett C; Jenkins D; Ettenberg SA; Cong F; Halleux C; Kneissel M
    J Bone Miner Res; 2014 Jan; 29(1):29-42. PubMed ID: 23901037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling.
    Li X; Zhang Y; Kang H; Liu W; Liu P; Zhang J; Harris SE; Wu D
    J Biol Chem; 2005 May; 280(20):19883-7. PubMed ID: 15778503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BMP signaling negatively regulates bone mass through sclerostin by inhibiting the canonical Wnt pathway.
    Kamiya N; Ye L; Kobayashi T; Mochida Y; Yamauchi M; Kronenberg HM; Feng JQ; Mishina Y
    Development; 2008 Nov; 135(22):3801-11. PubMed ID: 18927151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of Wnt signaling by Wise (Sostdc1) and negative feedback from Shh controls tooth number and patterning.
    Ahn Y; Sanderson BW; Klein OD; Krumlauf R
    Development; 2010 Oct; 137(19):3221-31. PubMed ID: 20724449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetics of Sost/SOST in sclerosteosis and van Buchem disease animal models.
    Sebastian A; Loots GG
    Metabolism; 2018 Mar; 80():38-47. PubMed ID: 29080811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SOST Inhibits Prostate Cancer Invasion.
    Hudson BD; Hum NR; Thomas CB; Kohlgruber A; Sebastian A; Collette NM; Coleman MA; Christiansen BA; Loots GG
    PLoS One; 2015; 10(11):e0142058. PubMed ID: 26545120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Wnt Signaling Pathway Inhibitor Sclerostin Inhibits Angiotensin II-Induced Aortic Aneurysm and Atherosclerosis.
    Krishna SM; Seto SW; Jose RJ; Li J; Morton SK; Biros E; Wang Y; Nsengiyumva V; Lindeman JH; Loots GG; Rush CM; Craig JM; Golledge J
    Arterioscler Thromb Vasc Biol; 2017 Mar; 37(3):553-566. PubMed ID: 28062506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-bone-mass-producing mutations in the Wnt signaling pathway result in distinct skeletal phenotypes.
    Niziolek PJ; Farmer TL; Cui Y; Turner CH; Warman ML; Robling AG
    Bone; 2011 Nov; 49(5):1010-9. PubMed ID: 21855668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss-of-function of ACVR1 in osteoblasts increases bone mass and activates canonical Wnt signaling through suppression of Wnt inhibitors SOST and DKK1.
    Kamiya N; Kaartinen VM; Mishina Y
    Biochem Biophys Res Commun; 2011 Oct; 414(2):326-30. PubMed ID: 21945937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Recent topics on bone remodeling].
    Shinoda Y; Ogata N; Chung UI; Kawaguchi H
    Clin Calcium; 2004 Jan; 14(1):70-4. PubMed ID: 15576958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostaglandin E2 signals through PTGER2 to regulate sclerostin expression.
    Genetos DC; Yellowley CE; Loots GG
    PLoS One; 2011 Mar; 6(3):e17772. PubMed ID: 21436889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sclerostin is a direct target of osteoblast-specific transcription factor osterix.
    Yang F; Tang W; So S; de Crombrugghe B; Zhang C
    Biochem Biophys Res Commun; 2010 Oct; 400(4):684-8. PubMed ID: 20816666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of sclerostin expression by mechanical loading and bone morphogenetic proteins in osteogenic cells.
    Papanicolaou SE; Phipps RJ; Fyhrie DP; Genetos DC
    Biorheology; 2009; 46(5):389-99. PubMed ID: 19940355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.